Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
Open Access
- 1 October 2009
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 11 (5) , 556-561
Abstract
This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum toleKeywords
This publication has 16 references indexed in Scilit:
- Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium ReportClinical Cancer Research, 2007
- Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with TemozolomideClinical Cancer Research, 2004
- Delayed repletion of O6-methylguanine—DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicityJournal of Neurosurgery, 2003
- O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNUBritish Journal of Cancer, 1996
- Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine: a comparative study in vitroBritish Journal of Cancer, 1996
- Activity of temozolomide in the treatment of central nervous system tumor xenografts.1995
- Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase1995
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992
- Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.1991
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990